Data updated: Mar 10, 2026
BYDUREON BCISE
EXENATIDE SYNTHETIC
Approved 2017-10-20
4
Indications
--
Phase 3 Trials
1
Priority Reviews
8
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2017-10-20
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SUSPENSION, EXTENDED RELEASE
BYDUREON BCISE Approval History
Loading approval history...
What BYDUREON BCISE Treats
4 FDA approvalsOriginally approved for its first indication in 2017 . Covers 4 distinct patient populations.
- Other (4)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BYDUREON BCISE FDA Label Details
ProBYDUREON BCISE Patents & Exclusivity
Latest Patent: Apr 2031
Patents (47 active)
US8895033*PED
Expires Apr 4, 2031
US8895033
Expires Oct 4, 2030
US8361972*PED
Expires Sep 21, 2028
US8361972
Expires Mar 21, 2028
US8501698*PED
Expires Dec 20, 2027
US8501698
Expires Jun 20, 2027
US8906851*PED
Expires Feb 18, 2027
US8329648*PED
Expires Feb 18, 2027
US9884092*PED
Expires Feb 18, 2027
US8329648
Expires Aug 18, 2026
+ 37 more patents
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.